NASDAQ: SLNSilence Therapeutics PLC Stock
$4.81-0.29 (-5.69%)
Updated Aug 29, 2025
SLN Price
$4.81
Fair Value Price
N/A
Market Cap
$226.97M
52 Week Low
$1.97
52 Week High
$20.48
P/E
N/A
P/B
-2.41x
P/S
10.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$27.37M
Earnings
-$79.40M
Gross Margin
78.5%
Operating Margin
-271.7%
Profit Margin
-290.1%
Debt to Equity
-0.76
Operating Cash Flow
-$86M
Beta
0.59
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SLN Overview
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SLN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SLN
Ranked#289 of 482
Ranked#289 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.88 | A | |
| $38.85 | A | |
| $306.05 | A |
Be the first to know about important SLN news, forecast changes, insider trades & much more!
SLN News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLN's cash and short-term investments ($114.16M) cannot cover SLN's cash burn for the next year ($179.81M), once increasing cash burn (107.81%) is accounted for
Interest Coverage Financials
SLN's profit margin has decreased (-65.5%) in the last year from (-224.6%) to (-290.1%)
Profit Margin Growth Financials
SLN's short-term assets ($148.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more SLN due diligence checks available for Premium users.
Valuation
SLN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-102.1x
Market
35.25x
SLN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.41x
Industry
4.56x
SLN's financial health
Profit margin
Revenue
$224.0k
Net Income
-$27.4M
Profit Margin
-12,211.6%
SLN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SLN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$165.2M
Liabilities
$71.1M
Debt to equity
-0.76
SLN's short-term assets ($148.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLN's short-term assets ($148.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.8M
Investing
-$1.6M
Financing
$1.0k
SLN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLN vs Biotech Stocks
Silence Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.